Citation for published version (APA):
Damani, A., Van Hemelrijck, M., Wulaningsih, W., Crawley, D., & Cahill, D. (2016). Are you now a good surgeon? T2 positive margin status as a quality outcome measure following Radical Prostatectomy. World Journal of Urology.
Are you now a good surgeon? T2 positive margin status as a quality outcome measure following Radical Prostatectomy
Arees Damani¹, Mieke Van Hemelrijck¹, Wahyu Wulaningsih¹, Danielle Crawley¹, Declan Cahill².

Affiliations:
1) King’s College London, Division of Cancer Studies, Cancer Epidemiology Group, London, UK
2) The Royal Marsden NHS Foundation Trust, London, UK

Corresponding author:
Arees Damani
King’s College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, Research Oncology, 3rd Floor, Bermondsey Wing, Guy’s Hospital, London
SE1 9RT,
Phone: +44(0)20 7188 7904

Email addresses of all authors:
arees.damani@kcl.ac.uk
mieke.vanhemelrijck@kcl.ac.uk
wahyu.wulaningsih@kcl.ac.uk
danielle.crawley@kcl.ac.uk
declan.cahill@kcl.ac.uk

Key words:
Radical Prostatectomy, Outcomes assessment, Prostate cancer, Positive margins, Laparoscopic surgery

Word Count: 180 (abstract) and 2,441 (manuscript)

Conflicts of interest:
There are no conflicts of interest to be stated for the corresponding author and all co-authors
Introduction

The gold standard measure of surgeon performance for radical prostatectomy would include patient reported outcomes such as continence, quality of life with PSA follow ups, however this is rarely practical in the clinical setting. There is therefore a need for a more easily attainable, unbiased marker of surgical performance. We recently showed that T2 positive margin rate is the most informative quality outcome measure with the least potential observer bias (1). This highlights the possible use of T2 positive margin rates as a single objective outcome measure indicative of surgeon skill. Positive surgical margins (PSMs) have been studied in depth to analyse their clinical implications following radical prostatectomy (RP). Stephenson et al. conducted a study looking at 11,521 patients who underwent a RP between 1987 and 2005 and found no association between margin status and cancer specific mortality within 15 years post RP. However, they did observe a positive association with biochemical recurrence, so that it is recommended to avoid PSMs where possible (2).

Intra-prostatic incision (IPI) is associated with significantly increased biochemical recurrence (BCR), compared to patients with negative surgical margins with or without extra-prostatic extension. The 5-year biochemical recurrence-free survival was only 77% for patients with intra-prostatic incision, compared to 94% for those without (P=<0.0001), according to Preston et al. (3). Similar results have also been shown in other studies (4, 5). There is thus a growing body of evidence to support PSMs as a prognostic factor indicative of biochemical recurrence following RP.

In addition to its value as a diagnostic predictor, PSM have been suggested to be a good indicator of surgeons’ performance. Vickers et al. showed that surgeons who performed higher volumes of RP showed a decrease in PSMs over time, with a plateau after 250 procedures – suggesting that PSM rates can be used to monitor
surgeons’ experience (6). Although this data was published for the open procedure, laparoscopic procedures have a similar learning curve as shown by Secin et al., who showed a similar learning curve plateauing after 200 to 250 cases (7). Whilst pathological factors have been shown to influence margin status, surgeon skill and experience also may play an important role. Eastham et al. showed that high volume surgeons had significantly lower PSM rates (8). It has been suggested that intra-prostatic incision may be a better quality measure of surgeon experience than PSM rates (9). However, rates of intra-prostatic incisions vary greatly between studies. This is potentially due to the difficulty in differentiating between true T2 positive margins and extra prostatic extension. (9-11).

We have therefore evaluated the clinical variables that may affect T2 PSMs to determine whether this can be used as an objective measurement of surgeon skill and experience.

**Methodology**

**Study population**

We obtained prospective data for 183 consecutive patients who underwent laparoscopic radical prostatectomy (LRP) between 2003 and 2009. A single surgeon carried out all procedures. The surgeon reported all data pre, peri and post-operatively. All data was also verified in the electronic medical records. Only patients with T2 stage disease as classified by TNM staging (12) were included in the study.

**Margin Status**

Information on margin status was collected post-operatively. A PSM was reported when cancer cells were seen touching or extending beyond the inked resection margin, and were all identified in one Pathology Department by 10 different consultant pathologists, using standard procedures. PSM location was described as apical, circumferential or both. The pathologists are all dedicated consultant
uropathologists employed in a teaching hospital. Inter-pathologist review of specimens is carried out as part of an internal-audit.

**Clinical variables**

Pre-operative, peri-operative, and post-operative variables were studied in relation to margin status.

Pre-operative variables included age at surgery, ethnicity, Gleason Score (primary and secondary), TNM staging, PSA, and percentage positive cores. Age at surgery was categorised into ≤60 and >60 as older age is an important clinical determinant of prostate cancer (13). Total Gleason score was divided into three categories (≤6, 7, ≥8) (14), which corresponded to different survival profiles (15). PSA was divided into categories of ≤10 and >10 ng/ml. The percentage of positive cores was studied as a categorical variable (<25%, 25-49%, ≥50%). Date of surgery was studied as a categorical variable (2003-2004, 2005-2006, 2007-2009), as a measure of increasing surgeon experience.

Peri-operative variables were reported by the surgeon and included operative time, blood loss and neurovascular bundle (NVB) resection status. NVB status was assessed as no NVB, unilateral and bilateral NVB. Operative time (minutes) was measured as the time from the first incision to the last suture. Blood loss (ml) was recorded from the suction system in theatre.

Post-operative variables studied included prostate weight as reported by the pathologists. Length of hospital stay (days) obtained from the medical record.

**Statistical Analysis**

Statistical analysis was carried out using Statistical Analysis Systems (SAS) release 9.4 (SAS Institute, Cary, NC).
Univariable logistic regression analysis was performed for each clinical variable to assess their associations with margin status. A test for trend was conducted by assigning categories as an ordinal scale. To further assess this association while adjusting for potential confounding factors, multivariable analysis was performed by incorporating all clinical variables in the model. Finally, to assess any differences by margin location only in patients with PSM (n=30), one-way ANOVA and Chi² tests were performed for each clinical variable with respect to the three margin locations (apical, circumferential or both).

Results
Descriptive statistics of the patient cohort for pre-operative variables are presented in Table 1, with peri and post-operative variables in Table 2. 53% of patients were >60 years of age at time of surgery. The majority was of a white background and presented with PSA ≤10 ng/ml (77%), with a Gleason score of ≤6 (60%). NVB resection was performed unilaterally in 29 patients (16%) and bilaterally in 68 (37%). Mean hospital stay was 2 days. 49.7% of procedures were carried out between 2007-2009, when the surgeon was more experienced.

Surgical stage showed a statistically significant correlation with PSM status in both univariate (P=0.035) (Table 3) and multivariate analysis (P=0.004) (Table 4). Patients with higher surgical stage of T2b and T2c were more likely to have PSMs (OR=8.7 (95%CI: 1.07-70.71) and OR=4.1 (95%CI: 0.52-33.27), respectively) than those with T2a disease. Earlier date of surgery was statistically significantly associated with higher PSM rates in both univariate (Table 3) and multivariate analysis (Table 4) (P=0.018). PSMs were also most prevalent in patients with prostatic weight between 20-59g. PSMs were not associated with the reporting pathologist (P=0.855).
In contrast with the univariate analysis, larger prostatic weight (>100g) showed a higher predictive value for PSM in multivariate analysis (Table 4). Multivariable analysis also showed NVB resection status to be associated with PSMs, with more PSM in patients in whom NVB resection was not attempted (P=0.037).

Finally, we assessed whether any of the clinical variables studied were differentially distributed across PSM locations (Table 5). Highest mean blood loss was observed in multifocal PSMs (apex and circumferential) (883.3ml, P=0.006). Patients with apical PSMs mostly had T2c disease, whereas those with circumferential PSMs had the highest proportion of T2b disease (P=0.01).

**Discussion**

Our multivariate analyses showed that several clinical variables are predictive of T2 PSMs, including nerve-sparing status and tumour characteristics. Fewer PSM were seen with later date of surgery, confirming the notion of a surgical learning curve in RP procedures. The reporting pathologist and Gleason score were not associated with T2 positive margin status.

PSMs have been extensively studied to determine their clinical significance. Several studies have outlined the prognostic value of PSMs (2, 10, 16-20). It is clear that while PSMs are not strongly linked to cancer-specific survival, PSMs are an important predictor of BCR. For these reasons, PSM rates are increasingly being reported as a quality measure, indicating superior surgeon experience and skill. However, few studies to date have investigated factors that may influence margin status apart from surgical experience and tumour characteristics. Although we limited our analysis to patients with pT2 stage, we assessed several clinical variables
predictive of prostate cancer prognosis including, pre-operative PSA and Gleason score.

Surgeon experience has a large impact on PSM rate. Vickers et al. showed that PSM rates were significantly improved when treated by a surgeon who had completed at least 250 procedures compared to a surgeon who had completed only 10 (21). Our study has also shown this to be the case. Patients who underwent a RP between 2007 and 2009 had a lower PSM rate, compared to those in 2005-2006 (OR=0.312 vrs OR=0.417). This was also true of patients undergoing surgery in 2005-2006 compared to those in 2003-2004 (OR=0.417 vrs OR=1). The British Association of Urological Surgeons (BAUS) recently published surgeon reported data regarding transfusion, length of stay and complication rates across the UK but positive margin rates were not published (22). The current study includes margin data and shows a clear link between surgeon experience and positive margin rates T2 disease. The surgeon in our study has had extensive training for the laparoscopic procedure. He undertook some assisting as a trainee and did part procedure cases as a primary surgeon. In addition he underwent 7 months of fellowship training in Institute Montsouris, Paris which involved assisting, and gaining dry and wet lab training.

Our study only included T2 disease, and therefore looked at the impact of surgical stage on PSMs on a finer basis. We showed a significant association between T2 PSMs and surgical stage between subclasses in T2 disease (T2 a, b and c). Increasing tumour volume makes incision of the prostate more likely in T2 disease. Lower prostatic weight has also been shown to be an independent predictor of IPI due to the surgical difficulty involved in removing a small gland. (9, 23-25). Marchetti et al. (2011) found that predicted probability of a PSM was 22% for patients with <25g prostates, which decreased to just 1% for those with >150g prostates (25). Our
study also showed lower prostatic weight (20-59g) to be a predictor of T2 PSMs in the univariate analysis. In multivariate analysis prostates >100g had highest PSM rates. Patients with large prostates constituted a small number of more difficult cases and hence resulted in higher positive margin rates. Higher blood loss was associated with multifocal PSMs (P=0.006). Higher blood loss is a surrogate for surgical difficulty and hence makes surgical incision of the prostate more likely.

PSMs have also been associated with nerve sparing status. Due to the close approximation of the NVBs to the postero-lateral prostate gland, this is the most common site for iatrogenic IPI (4, 5, 9, 10, 26). Here, NVB status was not associated with margin location in the multivariable analysis, contradicting the literature (27). Patients who did not undergo NVB sparing procedures had higher incidence of PSMs than those with nerve sparing procedures. Non-nerve sparing surgery was more likely in high volume T2 disease. High volume disease in the non-nerve spare group makes prostatic incision more likely (apex and base) and can explain why higher PSM rates were seen in this group of patients. A limit to our study was that information on the grade of nerve spare (partial, inter-fascial, intra-fascial) was not available as this may have an impact on the risk of PSMs.

IPI refers to iatrogenic incision into the prostate that contains cancer. There is great variability in the rates of IPI reported by different studies. For example, several studies have found incidence of IPI to be 1.8%-2.8% (9) (11, 28). However, some studies have reported rates of IPI as high as 20% (29). Indeed, in our study, 30 patients (16.4%) presented with PSMs in T2 disease (IPI). One possible explanation is difficulty in pathologic interpretation of surgical margin status, as has been highlighted by a number of studies (9-11). There is a recognised danger for over-calling PSMs because of difficulty in differentiating between extraprostatic extension (EPE) and IPI (10). Despite recently published guidelines on standardised handling
of RP specimens by the International Society of Urological Pathology (ISUP) (2009) there is still a lack of consistency in the reporting of surgical margins (30).

A study by van der Kwast et al.(31) highlights the inter-observer variation in the reporting of positive margin status. External review of pathology reports was carried out for patients in the European Organisation for Research and Treatment of Cancer trial (EORTC). There was only a 57.5% agreement for extra-prostatic extension, and 69.4% concordance for surgical margin status. A total of 24.9% of the cases that were called positive at the local hospital were subsequently called negative on review in the study. More recent evidence has contradicted these findings, showing agreement in over 87% of cases regarding margin status (32). This evidence supports the fact that pathologists may interpret PSMs differently and calls into question the objectivity of surgical margin status as a quality measure.

However in our study, we found no such correlation between the reporting pathologist and margin status in both univariate and multivariate analysis. Therefore, it seems unlikely that the reporting pathologist has an impact on T2 PSM rates reported by different surgeons. It is more likely that, any differences between T2 PSM rates reported by different surgeons, are down to surgical experience, and tumour characteristics, not external bias.

One of the particular strengths of this study was the use of data from a single surgeon. This removes the heterogeneity of surgeon skills, and allows valid comparisons of PSM rate over time. Only 30 PSMs were present in our study, and therefore reduced the statistical power of our analysis. However, our PSM rate was comparable with other studies of a similar nature, for example Kumano et al. (2009), suggesting that the population was representative (29). Another limitation of the current study was that data was missing for many of the patients in our database. This was particularly the case for nerve sparing status. In our study, 48 patients
(26.2%) were missing data on nerve sparing status. Of these 6 had a PSM at surgery, which represents 20% of the PSMs in our population. This may be one reason why our study contradicted the majority of the literature with regard to the association of NVB resection and PSMs. Time to surgery was not evaluated in our cohort and would be interesting to study in the future, as waiting time may lead to tumour growth and therefore higher risk of PSM than is predicted by the clinical variables.

Conclusion
In the absence of good patient reported outcomes, T2 positive margin rates are increasingly being used a quality outcome measure of surgeon experience. Our study has shown that T2 positive margin rates are not influenced by external biases such as the reporting pathologist but are affected by tumour characteristics and surgeon skill alone and can therefore be considered as an objective measure of surgeon skill.
| Pre-operative variables | Frequency/Mean | %/SD |
|-------------------------|----------------|------|
| Age at surgery (yrs)    |                |      |
| ≤60                     | 86             | 47.3 |
| >60                     | 96             | 52.7 |
| Date of Surgery         |                |      |
| 2003-2004               | 44             | 24.0 |
| 2005-2006               | 48             | 26.2 |
| 2007-2009               | 91             | 49.7 |
| Ethnicity               |                |      |
| Black                   | 37             | 20.2 |
| White                   | 134            | 73.2 |
| Other                   | 3              | 1.6  |
| Missing                 | 9              | 4.9  |
| PSA (ng/ml)             |                |      |
| ≤10                     | 141            | 77.0 |
| >10                     | 40             | 21.9 |
| Missing                 | 2              | 1.3  |
| Percentage cores positive (%) |      |      |
| <25%                    | 55             | 30.1 |
| 25-49%                  | 56             | 30.1 |
| ≥50%                    | 38             | 20.8 |
| Missing                 | 34             | 18.6 |
Table 2.

| Peri-operative variables | | |
|--------------------------|------------------|
| Mean Blood Loss (ml)     | 279              | 225             |
| Mean operative time (mins)| 159             | 37              |

Nerve sparing status

|                | None | 38  | 20.8 |
|----------------|------|-----|------|
| Unilateral     | 29   | 15.8|
| Bilateral      | 68   | 37.2|
| Missing        | 48   | 26.2|

Post-operative variables

| Mean Hospital stay (days) | 2     | 2.12 |

Prostate Weight (g)

|          | 20-59 | 100 | 54.6 |
|----------|-------|-----|------|
| 60-99    |       | 49  | 26.8 |
| ≥100     |       | 13  | 7.1  |
| Missing  |       | 21  | 11.5 |

Pathologist

|       | 1    | 67  | 36.6 |
|-------|------|-----|------|
| 2     | 7    | 3.8 |
| 3     | 10   | 5.5 |
| 4     | 53   | 29  |
| 5     | 9    |     | 4.9  |
|       | 6    | 1   | 0.5  |
|       | 7    | 11  | 6.0  |
|       | 8    | 1   | 0.5  |
|       | 9    | 5   | 2.7  |
|       | 10   | 4   | 2.2  |
| Missing| 15   | 8.2 |
| Surgical Stage |  |  |
|----------------|---|---|
| T2a            | 30| 16.4 |
| T2b            | 52| 28.4 |
| T2c            | 96| 52.5 |
| T2x            | 5 | 2.7  |
| **Total Gleason** |  |  |
| ≤6             | 109| 59.6 |
| 7              | 60 | 32.8 |
| ≥8             | 13 | 7.1  |
Table 3.

|                      | Positive surgical margin (N=30) | Negative surgical margins (N=153) | Odds ratio | 95% Confidence interval | P<sub>trend</sub> |
|----------------------|---------------------------------|-----------------------------------|------------|-------------------------|------------------|
| **Pre-operative variables** |                                 |                                   |            |                         |                  |
| **Age at surgery (yrs)** |                                 |                                   |            |                         | 0.057            |
| ≤60                  | 19 (22%)                        | 67 (78%)                          | 1          | Ref                     |                  |
| >60                  | 11 (11%)                        | 85 (89%)                          | 0.46       | 0.20-1.02               |                  |
| **Date of Surgery**   |                                 |                                   |            |                         | 0.011            |
| 2003-2004            | 13 (30%)                        | 31 (70%)                          | 1          | Ref                     |                  |
| 2005-2006            | 7 (15%)                         | 41 (85%)                          | 0.41       | 0.15-1.14               |                  |
| 2007-2009            | 10 (11%)                        | 81 (89%)                          | 0.29       | 0.12-0.74               |                  |
| **Ethnicity**        |                                 |                                   |            |                         | 0.052            |
| Black                | 9                               | 28                                | 1          | Ref                     |                  |
| White                | 21                              | 113                               | 0.58       | 0.24-1.40               |                  |
| Other + missing      | 0                               | 12                                | n/a        | n/a                     |                  |
| **PSA (ng/ml) (SD)** |                                 |                                   |            |                         | 0.093            |
| ≤10                  | 27                              | 114                               | 1          | Ref                     |                  |
| >10                  | 3                               | 37                                | 0.34       | 0.10-1.19               |                  |
| **Percentage cores positive (%)** |                     |                                   |            |                         | 0.720            |
| <25%     | 8 (15%) | 47 (85%) | 1 | Ref |
|---------|---------|----------|---|-----|
| 25-49%  | 10 (18%)| 46 (82%) | 1.28 | 0.46-3.52 |
| ≥50%    | 8 (21%) | 30 (79%) | 1.57 | 0.53-4.62 |
| Missing | 4       | 30       | 0.78 | 0.22-2.83 |

### Peri-operative variables

| Mean Blood Loss (mls) (SD) | 299.8 (363.7) | 274.8 (185.4) | 1.00 | 0.99-1.00 | 0.580 |
|---------------------------|----------------|----------------|------|-----------|-------|
| Mean operative time (mins) (SD) | 160.8 (39.06) | 158.0 (37.1) | 1.00 | 0.99-1.01 | 0.708 |
| Nerve sparing status | None | 9 | 29 | 1 | Ref |
| | Unilateral | 4 | 25 | 0.52 | 0.14-1.88 |
| | Bilateral | 11 | 57 | 0.62 | 0.23-1.67 |
| | Missing | 6 | 42 | 0.46 | 0.23-3.47 |

### Post-operative variables

| Mean Hospital stay (days) (SD) | 2.07 (1.2) | 2.02 (2.26) | 1.01 | 0.84-1.21 | 0.911 |
|------------------------------|------------|-------------|------|-----------|-------|
| Prostate Weight (g) | | | | | 0.035 |
| Stage       | Count | Percentage | p-value | CI             |
|-------------|-------|------------|---------|---------------|
| 20-59       | 24    | 24%        |         | 0.21-0.72     |
| 60-99       | 3     | 5%         |         | 0.06-0.72     |
| ≥100        | 2     | 15%        |         | 0.12-2.78     |
| Missing     | 1     | 20         |         | 0.02-1.24     |

Pathologist

| Pathologist | Count | Percentage | p-value | CI     |
|-------------|-------|------------|---------|--------|
| 1           | 10    | 57         |         | 1.47-39.21 |
| 2           | 4     | 3          | 7.60    | 0.07-5.56 |
| 3           | 1     | 9          | 0.63    | 0.58-3.84 |

| Surgical Stage (%) | Count | Percentage | p-value | CI     |
|--------------------|-------|------------|---------|--------|
| T2a                | 1     | 29         | 1       | Ref    |
| T2b                | 12    | 40         | 8.70    | 1.07-70.71 |
| Grade | T2c | T2x | Total Gleason |
|-------|-----|-----|---------------|
| G≤6   | 12  | 5   | 22 (          |
| G≥7   | 84  | 0   | 87            | 1  |
| G≥8   | 4.14| n/a | 0.187         |

| Grade | 7  | 0.44 | 0.17-1.15 |
|-------|----|------|-----------|
| G≥8   | 2  | 0.72 | 0.15-3.48 |
Table 4.

| Pre-operative variables | Multivariable OR | 95% CI | P\text{trend} |
|-------------------------|------------------|--------|--------------|
| Age at surgery (yrs)    |                  |        |              |
| ≤60                     | 1                | Ref    |              |
| >60                     | 0.24             | 0.06-0.95 | 0.042 |
| Date of Surgery         |                  |        |              |
| 2003-2004               | 1                | Ref    |              |
| 2005-2006               | 0.44             | 0.04-5.22 | 0.018 |
| 2007-2009               | 0.31             | 0.03-3.62 |        |
| Ethnicity               |                  |        |              |
| Black                   | 1                | Ref    |              |
| White                   | 0.71             | 0.19-2.70 |        |
| Other +missing          | n/a              | n/a    | n/a         |
| PSA (ng/ml)             |                  |        |              |
| ≤10                     | 1                | Ref    |              |
| >10                     | 0.29             | 0.06-1.45 |        |
| Percentage cores positive (%) |        |        |              |
| <25%                    | 1                | Ref    |              |
| 25-49%                  | 1.57             | 0.32-7.62 |        |
| ≥50%                    | 1.83             | 0.38-8.84 |        |
| Missing                 | 0.97             | 0.13-7.19 |        |
| Peri-operative variables |                  |        |              |
| Blood Loss (mls)        | 1.00             | 0.99-1.00 | 0.576 |
| Op time (mins)          | 0.99             | 0.97-1.01 | 0.458 |
| Nerve sparing status    |                  |        |              |

0.037
| Category      | Value 1 | Value 2 | Value 3 |
|---------------|---------|---------|---------|
| None          | 1       | Ref     |         |
| Unilateral    | 0.24    | 0.03-1.72 |         |
| Bilateral     | 0.19    | 0.04-1.00 |         |
| Missing       | 0.17    | 0.03-1.01 |         |

### Post-operative variables

| Variable                  | Value 1 | Value 2 | Value 3 |
|---------------------------|---------|---------|---------|
| **Surgical Stage**        |         | 0.004   |         |
| T2a                       | 1       | Ref     |         |
| T2b                       | 6.52    | 0.63-67.01 |         |
| T2c                       | 7.52    | 0.50-113.26 |        |
| T2x                       | n/a     | n/a     |         |
| **Prostate weight (g)**   |         | 0.031   |         |
| 20-59                     | 1       | Ref     |         |
| 60-99                     | 0.35    | 0.08-1.52 |         |
| ≥100                      | 1.29    | 0.13-12.96 |        |
| Missing                   | 0.16    | 0.02-1.64 |         |
| **Total Gleason**         |         | 0.148   |         |
| ≤6                        | 1       | Ref     |         |
| 7                         | 0.18    | 0.04-0.90 |         |
| ≥8                        | 0.63    | 0.08-4.84 |         |
| **Mean Hospital stay (days)** | 0.88   | 0.63-1.21 | 0.427  |
|                          | Apex (%) (N=15) | Circumferential (%) (N=12) | Apex and circumferential (%) (N=3) | P value |
|--------------------------|-----------------|----------------------------|-----------------------------------|---------|
| **Age at time of surgery (yrs)** |                 |                            |                                   | 0.898   |
| ≤60                      | 10 (62.5)       | 7 (58.3)                   | 2 (66.7)                          |         |
| >60                      | 5 (31.3)        | 5 (41.7)                   | 1 (33.3)                          |         |
| *Missing*                | 1 (6.3)         | 0 (0.0)                    | 0 (0.0)                           |         |
| **Ethnicity**            |                 |                            |                                   | 0.924   |
| Black                    | 4 (26.7)        | 4 (33.3)                   | 1 (33.3)                          |         |
| White                    | 11 (73.3)       | 8 (66.7)                   | 2 (66.7)                          |         |
| Other                    | 0 (0)           | 0 (0)                      | 0 (0)                             |         |
| **Mean PSA (ng/ml)**     |                 |                            |                                   | 0.189   |
| ≤10                      | 12 (80.0)       | 12 (100)                   | 3 (100)                           |         |
| >10                      | 3 (20.0)        | 0 (0)                      | 0 (0)                             |         |
| **Mean Percentage cores positive (%)** |             |                            |                                   | 0.057   |
| <25%                     | 0 (0)           | 7 (58.3)                   | 1 (33.3)                          |         |
| 25-49%                   | 7 (46.7)        | 2 (16.7)                   | 1 (33.3)                          |         |
| >50%                     | 5 (33.3)        | 2 (16.7)                   | 1 (33.3)                          |         |
| *Missing*                | 3 (20.0)        | 1 (8.3)                    | 0 (0)                             |         |
| **Mean Blood Loss (mls) (SD)** | 182.33 (87.7) | 300.83 (237.2)             | 883.33 (970.0)                    | 0.006   |
| **Mean operative time (mins) (SD)** | 153 (34.4) | 170.83 (45.9)              | 160 (34.6)                        | 0.515   |
| **Mean Hospital stay (days) (SD)** | 2.27 (1.3) | 1.67 (0.7)                 | 2.67 (2.1)                        | 0.297   |
|        | Mean Prostate Weight (g) | Pathologist | Nerve sparing status | Surgical Stage |
|--------|--------------------------|-------------|----------------------|---------------|
|        |                          |             |                      |               |
|        |                          | 0.144       | 0.535                | 0.010         |
|        |                          |             |                      |               |
|        |                          |             |                      |               |
|        |                          |             |                      |               |
| 20-59  | 12 (80.0) 10 (83.3) 2 (66.7) |             |                      |               |
| 60-99  | 2 (13.3) 1 (8.3) 0 (0.0)   |             |                      |               |
| ≥100   | 0 (0.0) 1 (8.3) 1 (33.3) |             |                      |               |
| Missing| 1 (6.7) 0 (0.0) 0 (0.0)   |             |                      |               |
|        |                          |             |                      |               |
|        | 1 7 (30.4) 3 (15.8) 0 (0.0) |             |                      |               |
|        | 2 1 (4.3) 2 (10.5) 1 (33.3) |             |                      |               |
|        | 3 0 (0.0) 1 (5.3) 0 (0.0) |             |                      |               |
|        | 4 5 (21.7) 5 (26.3) 1 (33.3) |             |                      |               |
|        | 5 0 (0.0) 0 (0.0) 0 (0.0) |             |                      |               |
|        | 6 0 (0.0) 0 (0.0) 0 (0.0) |             |                      |               |
|        | 7 2 (8.7) 1 (5.3) 0 (0.0) |             |                      |               |
|        | 8 0 (0.0) 0 (0.0) 0 (0.0) |             |                      |               |
|        | 9 0 (0.0) 0 (0.0) 1 (33.3) |             |                      |               |
|        | 10 0 (0.0) 0 (0.0) 0 (0.0) |             |                      |               |
|        | Missing=15 8 (34.8) 7 (36.8) 0 (0.0) |             |                      |               |
|        |                          |             |                      |               |
|        | None 3 (20.0) 5 (41.7) 1 (33.3) |             |                      |               |
|        | Unilateral 2 (13.3) 1 (8.3) 1 (33.3) |             |                      |               |
|        | Bilateral 5 (33.3) 5 (41.7) 1 (33.3) |             |                      |               |
|        | Missing 5 (33.3) 1 (8.3) 0 (0.0) |             |                      |               |
|        | T2a 0 (0.0) 0 (0.0) 1 (33.3) |             |                      |               |
|        | T2b 4 (26.7) 8 (66.7) 0 (0.0) |             |                      |               |
|        | T2c 9 (60.0) 2 (16.7) 1 (33.3) |             |                      |               |
| Parameter          | Category | Total | 6      | 7      | ≥8     | Missing |
|--------------------|----------|-------|--------|--------|--------|---------|
| T2x                |          | 2 (13.3) | 2 (16.7) | 1 (33.3) |
| Total Gleason      |          |        | 10 (62.5) | 10 (83.3) | 2 (66.7) |
| "6                 |          |        | 3 (18.8) | 2 (16.7) | 1 (33.3) |
| 7                  |          |        | 2 (12.5) | 0 (0.0)  | 0 (0.0)  |
| ≥8                 |          |        | 1 (6.3)  | 0 (0.0)  | 0 (0.0)  |
| Missing            |          |        |         |         |         |         |
| Date of Surgery    |          |        | 5 (33.3) | 7 (58.3) | 1 (33.3) |
| 2003-2004          |          |        | 4 (26.7) | 2 (16.7) | 1 (33.3) |
| 2005-2006          |          |        | 6 (40.0) | 3 (25.0) | 1 (33.3) |


Ethical standards

There are no ethical considerations to consider in this study.

Conflicts of interest

There are no conflicts of interest for any of the named authors.

Contributions

Arees Damani: Data Collection, data analysis, manuscript writing
Mieke Van Hemelrijck: Project development, data analysis, manuscript editing
Wulaningsih Wahyu: Data analysis, manuscript editing
Danielle Crawley: Data analysis, manuscript editing
Declan Cahill: Project development, data collection, manuscript editing
References

1. Mason S VHM, Brown C, Cahill D. Radical Prostatectomy Outcome Data: Which parameters are representative and reliable to publish? BAUS. 2015.
2. Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP, Jr., et al. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014;65(4):675-80.
3. Preston MA, Carriere M, Raju G, Morash C, Doucette S, Gerridzen RG, et al. The prognostic significance of capsular incision into tumor during radical prostatectomy. Eur Urol. 2011;59(4):613-8.
4. Chuang AY, Nielsen ME, Hernandez DJ, Walsh PC, Epstein JJ. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol. 2007;178(4 Pt 1):1306-10.
5. Shuford MD, Cookson MS, Chang SS, Shintani AK, Tsiatis A, Smith JA, Jr., et al. Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. J Urol. 2004;172(1):119-23.
6. Vickers A, Bianco F, Cronin A, Eastham J, Klein E, Kattan M, et al. The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. J Urol. 2010;183(4):1360-5.
7. Secin FP, Savage C, Abbou C, de La Taille A, Salomon L, Rassweiler J, et al. The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol. 2010;184(6):2291-6.
8. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003;170(6 Pt 1):2292-5.
9. Park SW, Readal N, Jeong BC, Humphreys EB, Epstein JJ, Partin AW, et al. Risk Factors for Intraprostatic Incision into Malignant Glands at Radical Prostatectomy. Eur Urol. 2014.
10. Yossepowitch O, Briganti A, Eastham JA, Epstein J, Graefen M, Montironi R, et al. Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol. 2014;65(2):303-13.
11. Chuang AY, Epstein JJ. Positive surgical margins in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy: histologic features and pitfalls. The American journal of surgical pathology. 2008;32(8):1201-6.
12. AJCC. What is Cancer Staging? 2002 [cited 2015 5/11/15]. Available from: https://cancerstaging.org/ references-tools/Pages/What-is-Cancer-Staging.aspx.
13. Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment. Cancer. 2006;107(10):2392-400.
14. Emerson RE, Koch MO, Daggy JK, Cheng L. Closest distance between tumor and resection margin in radical prostatectomy specimens: lack of prognostic significance. The American journal of surgical pathology. 2005;29(2):225-9.
15. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam
radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998;280(11):969-74.
16. Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH, et al. Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. The Journal of urology. 2010;183(6):2213-8.
17. Chalfin HJ, Dinizio M, Trock BJ, Feng Z, Partin AW, Walsh PC, et al. Impact of surgical margin status on prostate-cancer-specific mortality. BJU Int. 2012;110(11):1684-9.
18. Retel VP, Bouchardy C, Usel M, Neyroud-Caspar I, Schmidlin F, Wirth G, et al. Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study. BMC urology. 2014;14:86.
19. Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, et al. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naive patients. BJU Int. 2011;107(11):1748-54.
20. Boorjian SA, Karnes RJ, Crispe PL, Carlson RE, Rangel L, Bergstralh EJ, et al. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol. 2010;183(3):1003-9.
21. Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, et al. The surgical learning curve for prostate cancer control after radical prostatectomy. Journal of the National Cancer Institute. 2007;99(15):1171-7.
22. BAUS. Radical Prostatectomy Outcomes Data: BAUS; 2015 [cited 2015/10/2015]. Available from: http://www.baus.org.uk/patients/surgical_outcomes/prostatectomy/default.aspx.
23. Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol. 2005;174(5):1798-801; discussion 801.
24. Patel VR, Coelho RF, Rocco B, Orvieto M, Sivaraman A, Palmer KJ, et al. Positive surgical margins after robotic assisted radical prostatectomy: a multi-institutional study. J Urol. 2011;186(2):511-6.
25. Marchetti PE, Shikanov S, Razmara AA, Zagaja GP, Shalhav AL. Impact of prostate weight on probability of positive surgical margins in patients with low-risk prostate cancer after robotic-assisted laparoscopic radical prostatectomy. Urology. 2011;77(3):677-81.
26. Kwak KW, Lee HM, Choi HY. Impact of capsular incision on biochemical recurrence after radical perineal prostatectomy. Prostate cancer and prostate diseases. 2010;13(1):28-33.
27. Preston MA, Breau RH, Lantz AG, Morash C, Gerridzen RG, Doucette S, et al. The association between nerve sparing and a positive surgical margin during radical prostatectomy. Urologic oncology. 2015;33(1):18.e1-6.
28. Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, et al. Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? Urology. 2001;58(5):746-51.
29. Kumano M, Miyake H, Muramaki M, Kurashashi T, Takenaka A, Fujisawa M. Adverse prognostic impact of capsular incision at radical prostatectomy for Japanese men with clinically localized prostate cancer. International urology and nephrology. 2009;41(3):581-6.
30. Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011;24(1):48-57.

31. van der Kwast T, Collette L, Van Poppel H, Van Cangh P, Vekemans K, DaPozzo L, et al. Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). Virchows Arch. 2006;449(4):428-34.

32. Netto GJ, Eisenberger M, Epstein JI. Interobserver Variability in Histologic Evaluation of Radical Prostatectomy Between Central and Local Pathologists: Findings of TAX 3501 Multinational Clinical Trial. Urology. 2011;77(5):1155-60.